INSIGHTS ON DRUG DEVELOPMENT
-
Your AKTA Oligosynt™ System : It's More Than A Machine
Discover how early choices in oligo synthesis workflows shape performance. Learn what to consider across design, reagents, and system optimization to build a process ready for smooth scale‑up.
-
How To Capture Growth In The Expanding Metabolic Drug Market
Driven by GLP-1 success and rising obesity rates, R&D investment in metabolic disease therapies now rivals oncology, demanding rapid development to overcome market challenges.
-
Straight From The Source: A Live Q&A With The Inventors Of KinetiSol™
Experts discuss a solvent-free fusion process for amorphous solid dispersions, highlighting formulation flexibility, scale-up, process control, and early strategies to reduce risk and support commercialization.
-
Predictive Human Biology At Scale
Watch to explore applications of the Colon Intestine-Chip in studying cytokine-mediated inflammation, the effectiveness of anti-inflammatory therapies, and forthcoming immune cell recruitment.
-
Predicting Performance Of Lotions Through Rheological Characterization5/6/2026
Rheological testing shows how small formulation differences influence spreading, flow, and feel during use. With minimal sample volumes, these methods connect lab measurements to real‑world performance.
-
Navigating Nitrosamine Impurities In Pharmaceutical Drug Development3/3/2026
Understanding formation mechanisms and potency categorization allows developers to mitigate risks early, ensuring regulatory compliance and patient safety without compromising product performance.
-
3 Key Considerations In Gene Therapy Manufacturing7/15/2025
Viral vector-based gene therapies are redefining medicine. As developers navigate uncharted territory, Sybil Danby of Cytiva highlights three critical areas shaping the journey from discovery to patient access.
-
Accelerating Discovery Success With Structure-Guided Drug Design5/6/2026
Structure‑enabled drug discovery revealed a novel, druggable binding site in Artemis, enabling rapid SAR optimization and a ~500‑fold potency improvement against a challenging oncology target.
-
UPLC-MS/MS Determination Of GLP-1 Analogue7/17/2025
Discover a robust, evaporation-free method for analyzing liraglutide in human plasma using LC-MS/MS to ensure high sensitivity, reproducibility, and improved analyte recovery.
DRUG DEVELOPMENT SOLUTIONS
-
Advanced nanotechnology improves biologics with higher drug loads, better stability, new delivery routes, and enhanced performance in injectables, inhalation, and long‑acting therapies.
-
Reproducibility, reliability and carryover performance that meets your workflow demands, injection to injection, batch after batch.
ExionLC 2.0 and ExionLC 2.0+ systems provide full integration, control and compatibility with SCIEX mass spectrometers bringing together the speed and precision you expect for a complete solution that meets every challenge your lab faces.
-
Filterless readers provide consistent results with steady temperature regulation
The SpectraMax® ABS and ABS Plus absorbance microplate readers provide the flexibility, sensitivity, and convenience for a wide range of assays such as ELISAs, microbial growth, and protein quantitation. Both readers feature an 8-channel read head for fast reads and a subset feature, the temperature independent PathCheck sensor that automatically normalizes and ensures accurate absorbance values by detecting pipetting errors. Combined with a wide application base, industry-leading SoftMax® Pro Software and validation tools, these readers fit in every lab and every budget.
-
Waters has a complete portfolio of liquid chromatography and LC-MS solutions to provide you with accurate data to answer your lab's most pressing questions.
-
Successful development relies on a deep understanding of a molecule’s unique characteristics. We have the knowledge and expertise to realize the true potential of your molecule, regardless of its complexity.